Is lung stereotactic ablative radiotherapy safe after pneumonectomy?-a systematic review.

ABSTRACT: Patients treated with surgery for lung cancer are at risk of second primary lung cancers (SPLCs), which when localized, may be amenable to radical treatment. Treatment options, however, are limited due to reduced cardiopulmonary reserve and competing mortality risks. The aim of this study was to perform a systematic review of publications examining treatment planning considerations, clinical outcomes, and toxicity rates of stereotactic ablative radiotherapy (SABR) in patients who have previously undergone pneumonectomy. A systematic review of the literature was conducted in accordance with PRISMA guidelines using PubMed and EMBASE from inception to July 2018. Articles were limited to those published in the English language. Non-review articles with patients who received exclusively lung SA

SUBMITTER: Arifin AJ 

PROVIDER: S-EPMC7225144 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature